Labiotech.eu

News and Trends 27 Jul 2015

Roche exits €940M discovery alliance with Molecular Partners

Roche left the collaboration with Molecular Partners, walking away from a potential cancer treatment using the DARPin technology. The collaboration, entered in 2013, was worth up to €940M. Molecular Partners is a Swiss company focusing on immuno-oncology. The company has developed a platform generating small proteins called DARPins (Designed Ankyrin Repeat Proteins). These can target […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

Cardiovascular diseases kill around 2.6 million people each year and embody one of the biggest healthcare markets in the World. Not surprising to see Big Pharmas/Biotechs overactive in this field. What are their plans? Today, Sanofi‘s hypercholesterolemia therapy Praluent was recommended to the European market. It is a fully human monoclonal antibody developed in collaboration with the American Big Biotech Regeneron. But Amgen announced […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 26 Jul 2015

Roche’s Deal pushes Vifor’s split from Galenica

Switzerland’s biggest pharmacy network, Galenica, wants to split off the specialty pharma company Vifor Pharma. This could be done earlier than expected, thanks to a lucrative Roche deal. Galenica has made large investments in the pharma business over the recent years. Vifor Pharma is already a world leader when it comes to iron deficiency treatments. In […]

July 26, 2015 - 1 minutemin - By Philip Hemme

News and Trends 24 Jul 2015

MGB puts a new spin on fighting multi-resistant bacteria

MGB Biopharma wants to tackle multi-resistant bacteria with their newly developed anti-infectives. Its lead candidate, MGB-BP-3 is now entering Phase I. Biotech companies use several approaches when it comes to killing bacteria, especially when these are resistant against antibiotics. In our last news, we have seen, Ferring betting on bacteriophages or ELIGO using CRISPR on this purpose. The Scottish […]

July 24, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 23 Jul 2015

MorphoSys’ blood disorder antibody reaches Phase I

MorphoSys AG seems to be sitting on a goldmine with its Human Combinatorial Antibody Library (HuCAL). The German giant snatched the second milestone payment from Novartis this year. The latter will now initiate a Phase I test for a HuCAL antibody designed to treat blood disorders. MorphoSys landed some big accounts in the past. Pfizer, Bayer, […]

July 23, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 23 Jul 2015

Why is Global Bioenergies moving back to First-Generation Biofuels?

Second-generation biofuels have solved many problems caused by their predecessors, first-generation biofuels. The French synthetic biology company Global Bioenergies just announced that it has adapted its gaz-producing process to sucrose, a first-generation biofuel. Why would it make this step backwards? Global Bioenergies is one of the leading European industrial Biotech companies. It wants to replace fossil oil with a biosourced […]

July 23, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 23 Jul 2015

Man can See Again thanks to his Bionic Eye

Major Breakthrough in eye research! The world’s first ever dry Age Related Macular Degeneration patient received Second Sight Medical Products’ ‘bionic eye’. Initial tests on the 80-year-old individual with no central vision showed that the treatment allowed him to see the outline of people again. 80-year-old Ray Flynn, from Audenshaw in Manchester, is one of the 20 […]

July 23, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 23 Jul 2015

Biotech investors are back in Germany

Things are looking good for German Biotechs! At least, this is what the general mood at the international congress organized by the IZB on July 16th and 17th 2015 in Martinsried, near Munich, reflected. A bunch of international investors and decision makers gathered to show that the sector is picking up momentum again in Germany! The Innovation and Startup […]

July 23, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 22 Jul 2015

Sensorion raises an additional €8M to test its inner ear drug

Listen up! French biotech Sensorion just raised €8M through a private placement to advance its inner ear disease drug to Phase II. Since its IPO in April, the value of the company has quadrupled. Sensorion emerged in 2009 as a spin-off of Inserm, the French institute of health and medical research. It specialises in the treatment of […]

July 22, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Nanopore cashes in €100M to revolutionize Next-gen sequencing

Personalized medicine is now becoming a reality thanks to next-gen sequencing. Illumina still remains Number 1 in the field, but Oxford Nanopore is on its way up to the top of the charts. The UK-based company raised €100M to become a serious challenger with its cheap and small technology. Oxford Nanopore Technologies, a spin out […]

July 22, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer, announced today that data from its Phase I/II study in patients with multiple myeloma has been published in Nature Medicine. This is the first report on TCR engineered T-cell therapy that shows durable persistence in patients! After its successful intoduction on […]

July 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 21 Jul 2015

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

A new partnering deal in the trendy field of immune-oncology. Boston-based Agenus signed a €40M deal with Italian Biotech Diatheva to get antibodies, which are targeting a glycoprotein expressed on T cell and NK cell lymphocytes to boost the immune system of patients to fight major cancer. The Boston (Lexington)-based company Agenus went on the NASDAQ […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Roche exits €940M discovery alliance with Molecular Partners

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

Roche’s Deal pushes Vifor’s split from Galenica

MGB puts a new spin on fighting multi-resistant bacteria

MorphoSys’ blood disorder antibody reaches Phase I

Why is Global Bioenergies moving back to First-Generation Biofuels?

Man can See Again thanks to his Bionic Eye

Biotech investors are back in Germany

Sensorion raises an additional €8M to test its inner ear drug

Nanopore cashes in €100M to revolutionize Next-gen sequencing

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!